{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T10:51:17Z","timestamp":1791456677406,"version":"4.3.4"},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100025520","name":"Medical Research Future Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100025520","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ramaciotti Foundation"},{"DOI":"10.13039\/501100008810","name":"New South Wales Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008810","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Novel therapeutic agents are required to improve hypertension control globally, which remains one of the leading modifiable risk factors for premature cardiovascular mortality. Aldosterone synthase inhibitors (ASIs) are a novel class of agents that suppress aldosterone production and have demonstrated clinically meaningful blood pressure reductions in phase 2 and phase 3 trials in patients with uncontrolled and resistant hypertension. As these therapies approach clinical adoption, important questions remain regarding effects on cardiovascular and kidney outcomes, safety profile, and optimal positioning within existing treatment algorithms. This review synthesizes the current clinical evidence for ASIs, highlights key knowledge gaps, and examines practical considerations for their real-world implementation, including persistent pharmacodynamic effects after treatment withdrawal, short-term changes in glomerular filtration rate, the risk of hyperkalemia, and the potential role of multidisciplinary care models to support safe and effective adoption.<\/jats:p>","DOI":"10.1093\/ajh\/hpag074","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T11:57:27Z","timestamp":1783511847000},"page":"S97-S105","source":"Crossref","is-referenced-by-count":0,"title":["The challenge of introducing aldosterone synthase inhibitors into multidisciplinary practice"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9866-0805","authenticated-orcid":false,"given":"Lauren E","family":"Heath","sequence":"first","affiliation":[{"name":"The George Institute for Global Health, University of New South Wales , Sydney,","place":["Australia"]},{"name":"Department of Renal Medicine, Royal North Shore Hospital , Sydney,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil V","family":"Badve","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, University of New South Wales , Sydney,","place":["Australia"]},{"name":"Department of Renal Medicine, St. George Hospital , Sydney,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4620-4976","authenticated-orcid":false,"given":"Jun","family":"Yang","sequence":"additional","affiliation":[{"name":"Centre for Endocrinology and Reproductive Health, Hudson Institute of Medical Research , Clayton, Victoria,","place":["Australia"]},{"name":"Department of Medicine, Monash University , Clayton, Victoria,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9276-8380","authenticated-orcid":false,"given":"Brendon L","family":"Neuen","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, University of New South Wales , Sydney,","place":["Australia"]},{"name":"Department of Renal Medicine, Royal North Shore Hospital , Sydney,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"2026100806031211100_hpag074-B1","author":"World Health Organization","year":"2026"},{"key":"2026100806031211100_hpag074-B2","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","article-title":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants","volume":"398","author":"Zhou","year":"2021","journal-title":"Lancet"},{"key":"2026100806031211100_hpag074-B3","doi-asserted-by":"publisher","first-page":"e07","DOI":"10.15420\/ecr.2023.51","article-title":"The global burden of resistant hypertension and potential treatment options","volume":"19","author":"Buso","year":"2024","journal-title":"Eur Cardiol"},{"key":"2026100806031211100_hpag074-B4","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1210\/clinem\/dgaf284","article-title":"Primary aldosteronism: an endocrine society clinical practice guideline","volume":"10","author":"Adler","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026100806031211100_hpag074-B5","doi-asserted-by":"publisher","first-page":"289","DOI":"10.7326\/M20-4873","article-title":"Testing for primary aldosteronism and mineralocorticoid receptor antagonist use among U.S. Veterans: a retrospective cohort study","volume":"174","author":"Cohen","year":"2021","journal-title":"Ann Intern Med"},{"key":"2026100806031211100_hpag074-B6","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3Nov21","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"2026100806031211100_hpag074-B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41574-022-00730-2","article-title":"Primary aldosteronism\u2014a multidimensional syndrome","volume":"18","author":"Turcu","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"2026100806031211100_hpag074-B8","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1161\/HYPERTENSIONAHA.122.17964","article-title":"Aldosterone as a mediator of cardiovascular damage","volume":"79","author":"Buffolo","year":"2022","journal-title":"Hypertension"},{"key":"2026100806031211100_hpag074-B9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/HJH.0000000000002216","article-title":"Renal damage in primary aldosteronism: a systematic review and meta-analysis","volume":"38","author":"Monticone","year":"2020","journal-title":"J Hypertens"},{"key":"2026100806031211100_hpag074-B10","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1093\/eurheartj\/ehac352","article-title":"Aldosterone in chronic kidney disease and renal outcomes","volume":"43","author":"Verma","year":"2022","journal-title":"Eur Heart J"},{"key":"2026100806031211100_hpag074-B11","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","article-title":"Effect of spironolactone on blood pressure in subjects with resistant hypertension","volume":"49","author":"Chapman","year":"2007","journal-title":"Hypertension"},{"key":"2026100806031211100_hpag074-B12","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/ejhf.1182","article-title":"Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish heart failure registry","volume":"20","author":"Savarese","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026100806031211100_hpag074-B13","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa2507109Oct8","article-title":"Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension","volume":"393","author":"Flack","year":"2025","journal-title":"N Engl J Med"},{"key":"2026100806031211100_hpag074-B14","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of baxdrostat for Treatment-Resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"key":"2026100806031211100_hpag074-B15","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2501440May7","article-title":"Lorundrostat efficacy and safety in patients with uncontrolled hypertension","volume":"392","author":"Laffin","year":"2025","journal-title":"N Engl J Med"},{"key":"2026100806031211100_hpag074-B16","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1001\/jama.2023.16029Sep26","article-title":"Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the Target-HTN randomized clinical trial","volume":"330","author":"Laffin","year":"2023","journal-title":"JAMA"},{"key":"2026100806031211100_hpag074-B17","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/S0140-6736(25)02549-8Mar7","article-title":"Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"407","author":"Azizi","year":"2026","journal-title":"Lancet"},{"key":"2026100806031211100_hpag074-B18","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1056\/nejmc2508629","article-title":"Phase 2a study of baxdrostat in primary aldosteronism","volume":"393","author":"Turcu","year":"2025","journal-title":"N Engl J Med"},{"key":"2026100806031211100_hpag074-B19","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1001\/jama.2025.9413","article-title":"Lorundrostat in participants with uncontrolled hypertension and treatment-resistant hypertension","volume":"334","author":"Saxena","year":"2025","journal-title":"JAMA"},{"key":"2026100806031211100_hpag074-B20","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-XJan27","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet"},{"key":"2026100806031211100_hpag074-B21","doi-asserted-by":"publisher","first-page":"100617","DOI":"10.1016\/j.lanepe.2023.100617Jun1","article-title":"Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021","volume":"29","author":"Malik","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"2026100806031211100_hpag074-B22","doi-asserted-by":"publisher","first-page":"1423027","DOI":"10.3389\/fendo.2024.1423027","article-title":"Evaluating the role of aldosterone synthesis on adrenal cell fate","volume":"15","author":"Aminuddin","year":"2024","journal-title":"Front Endocrinol"},{"key":"2026100806031211100_hpag074-B23","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1210\/js.2017-00134","article-title":"Aldosterone-producing cell clusters frequently harbor somatic mutations and accumulate with age in normal adrenals","volume":"1","author":"Omata","year":"2017","journal-title":"J Endocr Soc"},{"key":"2026100806031211100_hpag074-B24","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1097\/HJH.0000000000004218","article-title":"Prolonged aldosterone suppression and renin upregulation after baxdrostat","volume":"44","author":"Rutten","year":"2026","journal-title":"J Hypertens"},{"key":"2026100806031211100_hpag074-B25","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1681\/ASN.0000000849","article-title":"Efficacy and safety of baxdrostat in participants with CKD and uncontrolled hypertension: a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Dwyer","year":"2026","journal-title":"J Am Soc Nephrol"},{"key":"2026100806031211100_hpag074-B26","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41591-025-04057-z","article-title":"A meta-analysis of albuminuria as a surrogate endpoint for kidney failure","volume":"32","author":"Heerspink","year":"2026","journal-title":"Nat Med"},{"key":"2026100806031211100_hpag074-B27","author":"Boehringer Ingelheim","year":"2026"},{"key":"2026100806031211100_hpag074-B28","author":"AstraZeneca","year":"2026"},{"key":"2026100806031211100_hpag074-B29","author":"AstraZeneca","year":"2026"},{"key":"2026100806031211100_hpag074-B30","author":"AstraZeneca","year":"2026"},{"key":"2026100806031211100_hpag074-B31","author":"Boehringer Ingelheim","year":"2026"},{"key":"2026100806031211100_hpag074-B32","author":"Boehringer Ingelheim","year":"2026"},{"key":"2026100806031211100_hpag074-B33","author":"Boehringer Ingelheim","year":"2026"},{"key":"2026100806031211100_hpag074-B34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1161\/HYPERTENSIONAHA.116.07939","article-title":"Specific aldosterone synthase inhibition","volume":"69","author":"Schneider","year":"2017","journal-title":"Hypertension"},{"key":"2026100806031211100_hpag074-B35","author":"University Medical Center Groningen","year":"2025"},{"key":"2026100806031211100_hpag074-B36","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1093\/ajh\/hpad013","article-title":"Nonadherence is common in patients with apparent resistant hypertension: a systematic review and meta-analysis","volume":"36","author":"Bourque","year":"2023","journal-title":"Am J Hypertens"},{"key":"2026100806031211100_hpag074-B37","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1210\/clinem\/dgae145","article-title":"The spectrum of dysregulated aldosterone production: an international human physiology study","volume":"109","author":"Parksook","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026100806031211100_hpag074-B38","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1210\/jc.2016-1472","article-title":"Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis","volume":"101","author":"K\u00e4yser","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2026100806031211100_hpag074-B39","doi-asserted-by":"publisher","first-page":"408","DOI":"10.5694\/mja2.51438","article-title":"Detecting primary aldosteronism in Australian primary care: a prospective study","volume":"216","author":"Libianto","year":"2022","journal-title":"Med J Aust"},{"key":"2026100806031211100_hpag074-B40","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","article-title":"Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies","volume":"6","author":"Williams","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026100806031211100_hpag074-B41","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"2026100806031211100_hpag074-B42","doi-asserted-by":"publisher","first-page":"102576","DOI":"10.1016\/j.eclinm.2024.102576","article-title":"Safety and efficacy of once-daily dexfadrostat phosphate in patients with primary aldosteronism: a randomised, parallel group, multicentre, phase 2 trial","volume":"71","author":"Mulatero","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2026100806031211100_hpag074-B43","author":"AstraZeneca","year":"2026"},{"key":"2026100806031211100_hpag074-B44","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.5646\/ch.2025.31.e41","article-title":"Efficacy and safety of selective aldosterone synthase inhibitors in uncontrolled hypertension: a systematic review and meta-analysis of randomized controlled trials","volume":"31","author":"Louat","year":"2025","journal-title":"Clin Hypertens"},{"key":"2026100806031211100_hpag074-B45","article-title":"2026 AHA\/ACC\/ADA\/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. JACC. 2026;87 (22_Supplement):e1889-e2007. https:\/\/doi.org\/10.1016\/j.jacc.2026.03.056","author":"Ndumele"},{"key":"2026100806031211100_hpag074-B46","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41569-021-00559-8","article-title":"Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension","volume":"18","author":"Zhou","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"2026100806031211100_hpag074-B47","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.mayocp.2024.08.026","article-title":"Prescribing patterns of SGLT2 inhibitors and GLP-1 agonists in patients with type 2 diabetes at cardiology, endocrinology and primary care visits","volume":"100","author":"Dixon","year":"2025","journal-title":"Mayo Clin Proc"},{"key":"2026100806031211100_hpag074-B48","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/cvr\/cvaf235","article-title":"Obesity, aldosterone, and natriuretic peptides in patients with heart failure and reduced ejection fraction","volume":"122","author":"Matsumoto","year":"2026","journal-title":"Cardiovasc Res"},{"key":"2026100806031211100_hpag074-B49","doi-asserted-by":"publisher","first-page":"e114-e218","DOI":"10.1161\/CIR.0000000000001356","article-title":"2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"152","author":"Jones","year":"2025","journal-title":"Circulation"},{"key":"2026100806031211100_hpag074-B50","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1161\/HYPERTENSIONAHA.122.20810","article-title":"Improved persistence to medication, decreased cardiovascular events and reduced all-cause mortality in hypertensive patients with use of single-pill combinations: results from the START-study","volume":"80","author":"Schmieder","year":"2023","journal-title":"Hypertension"},{"key":"2026100806031211100_hpag074-B51","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 International society of hypertension global hypertension practice guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension"},{"key":"2026100806031211100_hpag074-B52","author":"American College of Cardiology","year":"2026"},{"key":"2026100806031211100_hpag074-B53","doi-asserted-by":"publisher","first-page":"e012834","DOI":"10.1161\/CIRCOUTCOMES.125.012834","article-title":"Patient perspectives on a polypill strategy for heart failure with reduced ejection fraction: a convergent-parallel mixed methods study embedded in a randomized clinical trial","volume":"19","author":"Keshvani","year":"2026","journal-title":"Circ Popul Health Outcomes"},{"key":"2026100806031211100_hpag074-B54","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1001\/jama.2024.0728","article-title":"RNA interference with zilebesiran for mild to moderate hypertension","volume":"331","author":"Bakris","year":"2024","journal-title":"JAMA"},{"key":"2026100806031211100_hpag074-B55","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1001\/jama.2025.6681","article-title":"Add-On treatment with zilebesiran for inadequately controlled hypertension: the KARDIA-2 randomized clinical trial","volume":"334","author":"Desai","year":"2025","journal-title":"JAMA"},{"key":"2026100806031211100_hpag074-B56","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1161\/CIRCULATIONAHA.120.049730Nov10","article-title":"Nighttime blood pressure phenotype and cardiovascular prognosis","volume":"142","author":"Kario","year":"2020","journal-title":"Circulation"},{"key":"2026100806031211100_hpag074-B57","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1016\/S0140-6736(25)02014-8","article-title":"Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial","volume":"406","author":"Heerspink","year":"2025","journal-title":"Lancet"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/39\/Supplement_1\/S97\/71667105\/hpag074.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/39\/Supplement_1\/S97\/71667105\/hpag074.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T10:03:19Z","timestamp":1791453799000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/39\/Supplement_1\/S97\/8875940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":57,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2026,10,8]]},"published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpag074","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"value":"0895-7061","type":"print"},{"value":"1941-7225","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,10,1]]}}}